FDA仅批准通用白叶酸用于罕见的脑叶酸缺乏症，不适用于自闭症。 FDA approves generic leucovorin only for rare cerebral folate deficiency, not autism.

林业发展局批准了一种通用的Leucovorin,用于治疗一种稀有的遗传障碍,一种脑叶受体1基因突变引起的脑叶酸缺乏症,影响不到百万人中的1人。 The FDA has approved a generic version of leucovorin for treating a rare genetic disorder, cerebral folate deficiency caused by a mutation in the folate receptor 1 gene, affecting fewer than 1 in a million people. 批准仅限于这一特定条件,它引起神经学问题,如缉获和发育迟缓,而不是更广泛的自闭症。 The approval is limited to this specific condition, which causes neurological issues like seizures and developmental delays, not autism more broadly. 尽管早些时候官员声称该药物可以帮助许多自闭症儿童,但林业发展局表示,其审查发现,没有足够的证据支持这种使用。 Despite earlier claims by officials that the drug could help many autistic children, the FDA stated its review found no sufficient evidence to support such use. 撤回了为支持而引用的一项关键研究,主要医疗团体不建议例行使用。 A key study cited in support was retracted, and major medical groups do not recommend routine use. 白宫事件后,处方激增,造成短缺,促使林业发展局允许进口。 Prescriptions surged after a White House event, causing shortages and prompting the FDA to allow imports. 将自闭症与阻塞抗体联系起来的基本理论仍未得到证实。 The underlying theory linking autism to folate-blocking antibodies remains unproven.